Everett E. Vokes

80.0k citations
774 papers · 36.5k · 10 hit papers · h-index 95

Impact in

    • Head and Neck Cancer Studies
  • Oncology top 0.02%
    • Lung Cancer Research Studies
    • Colorectal Cancer Treatments and Studies
    • Cancer Immunotherapy and Biomarkers

Papers in

    • Lung Cancer Research Studies 129
    • Cancer Immunotherapy and Biomarkers 54
    • Cancer Diagnosis and Treatment 44
    • Lung Cancer Treatments and Mutations 205
    • Lung Cancer Diagnosis and Treatment 109

Everett E. Vokes

750 papers receiving 35.7k citations

Everett E. Vokes's Hit Papers

Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups 2008 · 696 citations
6960+11+22Years since publication50010001.5k

Peers

Everett E. Vokes
Comparison fields: 5 of 173
  • Otorhinolaryngology 8.3k
  • Oncology 13.6k
  • Pulmonary and Respiratory Medicine 10.8k
  • Cancer Research 2.4k
  • Speech and Hearing 709
Replace Jean‐Pierre Pignon with:
Jean‐Pierre Pignon France
Quynh‐Thu Le United States
Arlene A. Forastiere United States
Ezra E.W. Cohen United States
Jens Overgaard Denmark
Eric K. Rowinsky United States
Corey J. Langer United States
Søren M. Bentzen United States
Jacek Jassem Poland
José Baselga United States
Everett E. Vokes relative to Jean‐Pierre Pignon France Jean‐Pierre Pignon's profile →
Citations per field
00.5×4.5×
Jean‐Pierre Pignon · 1×
Citations per year

Countries citing papers authored by Everett E. Vokes

Since Specialization
Citations

This map shows the geographic impact of Everett E. Vokes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Everett E. Vokes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Everett E. Vokes more than expected).

Fields of papers citing papers by Everett E. Vokes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Everett E. Vokes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Everett E. Vokes. The network helps show where Everett E. Vokes may publish in the future.

Co-authors

The 25 scholars most cited alongside Everett E. Vokes, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Everett E. Vokes Line = papers co-authored together Everett E. Vokes links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 774 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Head and Neck Cancer
Hit paper breakdown →
19931818
2
Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
Hit paper breakdown →
20001123
3
Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan
Hit paper breakdown →
2004697
4
Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups
Hit paper breakdown →
2008696
5
Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
Hit paper breakdown →
2003658
6
Lung cancer
Hit paper breakdown →
2000530
7
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
Hit paper breakdown →
2002524
8
Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
Hit paper breakdown →
2008495
9
Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Hit paper breakdown →
2003493
10
The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy-head and neck scale: A study of utility and validity
Hit paper breakdown →
1996457
11 2004431
12
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
1994410
13 1996397
14 2001372
15 2005360
16 2009350
17 2007347
18 2007337
19 2005300
20 1990294

About Everett E. Vokes

Everett E. Vokes is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Otorhinolaryngology, Surgery and Molecular Biology, having authored 774 papers that have together received 36.5k indexed citations. Recurring topics across this work include Head and Neck Cancer Studies (230 papers), Lung Cancer Treatments and Mutations (205 papers), Lung Cancer Research Studies (129 papers), Lung Cancer Diagnosis and Treatment (109 papers), Cancer Immunotherapy and Biomarkers (54 papers), Cancer Diagnosis and Treatment (44 papers), Cancer Genomics and Diagnostics (41 papers) and Head and Neck Surgical Oncology (35 papers). The work is most often cited by research in Otorhinolaryngology (8.3k citations), Oncology (13.6k citations), Pulmonary and Respiratory Medicine (10.8k citations), Cancer Research (2.4k citations) and Speech and Hearing (709 citations). Everett E. Vokes has collaborated with scholars based in United States, France and Canada. Frequent co-authors include Ralph R. Weichselbaum, Daniel J. Haraf, Waun Ki Hong, Ezra E.W. Cohen, Scott M. Lippman, Joseph K. Salama, Kerstin Stenson, Tanguy Y. Seiwert, Ann M. Mauer and Walter M. Stadler. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Oncology, International Journal of Radiation Oncology*Biology*Physics and Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact